Oral bisphosphonates and osteonecrosis of the jaw: Are the MHRA recommendations appropriate?

Menopause International

Volumn 13, Issue 2, 2007, Pages 54-55

  Compston, Juliet ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; ALENDRONIC ACID; ANTINEOPLASTIC AGENT; GLUCOCORTICOID; IBANDRONIC ACID; RISEDRONIC ACID;

BONE NECROSIS; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; JAW DISEASE; NOTE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; UNITED KINGDOM; WOMEN'S HEALTH; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG HALF LIFE; DRUG WITHDRAWAL; EDITORIAL; EVIDENCE BASED PRACTICE; JAW OSTEONECROSIS; MEDICAL SOCIETY; NEOPLASM; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT COUNSELING; PREVENTIVE DENTISTRY; RISK ASSESSMENT;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; GREAT BRITAIN; HUMANS; JAW DISEASES; OSTEONECROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PRACTICE GUIDELINES; WOMEN'S HEALTH;

EID: 36049010739     PISSN: 17540453     EISSN: None     Source Type: Journal    
DOI: 10.1258/175404507780796415     Document Type: Editorial

References (4)

1. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy. Expert panel recommendations. J Am Dent Assoc 2006; 137: 1144–50.
2. Woo SB, Hellstein JW, Kalmar JR, et al. Systematic review: Bisphosphonates and osteonecrosis of the jaw. Ann Intern Med 2006; 144: 753–61.
3. Shane E, Goldring S, Christakos S, et al. Osteonecrosis of the jaw: more research needed. J Bone Miner Res 2006; 21: 1503–5.
4. Commission on Human Medicines, MRHA. Osteonecrosis of the jaw with bisphosphonates. Current Problems in Pharmacovigilance 2006; 31: 4–5.